At the news
? NEUTRALIMPACT 2/10 SC 13G/A filed Nov 5, 2026 at 13:10 ET
FMR LLC (Fidelity) filed an amended Schedule 13G reporting beneficial ownership of 9,307,349 shares of Arrowhead Pharmaceuticals common stock as of September 30, 2026, representing 6.6% of shares outstanding. This is a routine passive stake update with no change in investment intent.
- FMR LLC reports 9,307,349 shares of ARWR common stock as of September 30, 2026
- Stake represents 6.6% of shares outstanding
- Filing is an amendment to Schedule 13G, confirming passive investment intent
- Filing made under Rule 13d-1(b), indicating ordinary course investment activity
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access